Navigation Links
Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Date:5/19/2008

GREENWICH, Conn., May 19 /PRNewswire/ -- Helix Health, the first U.S. stand-alone genomic medicine practice, is hosting a 90-minute webcast this Wednesday, May 21, 2008 from 1:00-2:30 PM EDT examining:
How Genomic Medicine Is Changing the Management of Breast & Ovarian Cancer

To register, point your browser here http://event.netbriefings.com/event/helixhealth/register.html .

Every hour, 150 people in the United States are diagnosed with cancer. There is a growing number of people who are not willing to wait for that diagnosis. They are undergoing genetic testing to discover, and to know what they must do to manage these risks... personalized medicine for effective heath care management.

Topics:

What should a doctor and patient do when a patient tests positive?

What is the risk in taking a "wait and see" approach?

Are there alternatives to radical surgery?

What are potential tort issues in predictive genetic testing and medical

uses of genetic tests?

Panel:

Steven A.R. Murphy, MD - Clinical Genetics Fellow at Yale School of

Medicine, and Helix Health's Managing Partner will moderate the panel.

Barbara A. Ward, MD - Director, The Breast Center of Greenwich Hospital;

principal investigator of the STAR Trial

http://www.ynhh.org/healthlink/cancer/cancer_7_99.html; surgical

oncologist affiliated with Yale-New Haven Health System.

Jessica Queller - author of Pretty Is What Changes; television writer for

Felicity, The Gilmore Girls and One Tree Hill. Writer/producer on Gossip

Girl.

Jennifer Ibrahim, MD - clinical geneticist specializing in preconception

genetics as well as familial cancer syndromes.

David Ewing Duncan - bestselling author of Masterminds: Genius, DNA and

the Quest to Rewrite Life; Director, Center for Life Sciences Policy, UC

Berkeley; Chief Correspondent and co-host of National Public Radio's

"Biotech Nation".

Gary E. Marchant - Ph.D. J.D., Lincoln Professor of Emerging

Technologies, Law & Ethics, Sandra Day O'Connor College of Law; Executive

Director, Center for Law, Science & Technology, Professor, School of Life

Sciences Arizona State University.

Registration

To register, point your browser here http://event.netbriefings.com/event/helixhealth/register.html

Registration is limited, so please register soon.

If you are unable to attend, a podcast of the session will soon be available on the Helix Health website. http://www.helixhealth.org/

About Helix Health, PLLC/LLC - a medical practice that is bringing genomic medicine to health care. With offices in Greenwich, CT and New York, NY, Helix Health offers patients and their physicians expertise in genomic medicine and provides the tools required to take full advantage of genetic testing.

Contact info@helixhealth.org for more information, or visit http://www.helixhealth.org/


'/>"/>
SOURCE Helix Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
5. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the ... – London is home to Ontario’s leading day spa and one of Canada’s few ... began with a unique concept to combine spa services with hair and beauty ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... May 31, 2016 , ... TeaZa® Energy, LLC announces ... on World No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be ... this summer. , The new flavor is best described as a juicy, taste ...
Breaking Medicine News(10 mins):